Comparison · Updated
Semaglutide VS Retatrutide
Short answer
Semaglutide has stronger published evidence than Retatrutide: tier S (Approved) vs tier A (Controlled human trials).
Semaglutide is FDA-approved (Ozempic, Wegovy, Rybelsus, 2017); Retatrutide is not FDA-approved.
Semaglutide is not on the WADA Prohibited List; Retatrutide is prohibited in sport by WADA under section S0.
01
Side by side
| Field | Semaglutide | Retatrutide |
|---|---|---|
| Evidence tier | S Tier S · Approved | A Tier A · Controlled human trials |
| Tier rationale | Multiple phase 3 RCTs (SUSTAIN, STEP, SELECT); FDA-approved in 2017 (Ozempic), later as Wegovy and Rybelsus, and authorised by the EMA. | Phase 2 RCTs (NEJM 2023, Lancet 2023) and phase 3 RCTs (TRIUMPH-1, NEJM 2026; TRIUMPH-2/-3/-4); not approved by any regulator as of November 2026. |
| FDA status | Approved (2017) Ozempic, Wegovy, RybelsusApproved for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021). | Not approvedInvestigational; Lilly has said it plans to submit a US Biologics License Application in Q1 2027. |
| Other approvals | None listed | None listed |
| WADA | Not on the Prohibited List | Prohibited · S0Non-approved substances |
| Family | Metabolic | Metabolic |
| Residues | 31amino acids | 39amino acids |
| Molecular weight | 4,113.6 Da | 4,731.3 Da |
| Formula | C187H291N45O59 | C221H342N46O68 |
| Discovered | 2015Discovery published by Novo Nordisk scientists (Lau et al., J Med Chem 2015). | 2022Discovery and early clinical data published by Eli Lilly as LY3437943 (Coskun et al., Cell Metab 2022). |
| Routes studied | Subcutaneous | Subcutaneous |
| Mechanism | Semaglutide is a GLP-1 receptor agonist with 94% homology to native GLP-1, modified with a C18 fatty diacid chain enabling albumin binding and once-weekly pharmacokinetics. It activates GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), the gut (slowing gastric emptying), and the hypothalamus (reducing appetite and food reward signaling). | Retatrutide is a triple incretin receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors. GLP-1 and GIP receptor activation reduces appetite and improves insulin secretion, while glucagon receptor agonism increases energy expenditure and hepatic fatty acid oxidation, producing additive weight loss effects. |
| Safety notes | FDA-approved with robust Phase III data. | Gastrointestinal events (nausea, diarrhea, vomiting) were the most common adverse events in phase 2 and phase 3 trials and were dose-related. |
| Cited studies | 3 studies | 2 studies |
02
Questions
- Which has stronger evidence, Semaglutide or Retatrutide?
- Semaglutide has stronger published evidence than Retatrutide: tier S (Approved) vs tier A (Controlled human trials). Semaglutide: Multiple phase 3 RCTs (SUSTAIN, STEP, SELECT); FDA-approved in 2017 (Ozempic), later as Wegovy and Rybelsus, and authorised by the EMA. Retatrutide: Phase 2 RCTs (NEJM 2023, Lancet 2023) and phase 3 RCTs (TRIUMPH-1, NEJM 2026; TRIUMPH-2/-3/-4); not approved by any regulator as of November 2026. Tiers rate the strength of published evidence, not effectiveness.
- Is Semaglutide FDA-approved?
- Semaglutide is FDA-approved (Ozempic, Wegovy, Rybelsus, 2017). Approved for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021).
- Is Retatrutide FDA-approved?
- Retatrutide is not FDA-approved. Investigational; Lilly has said it plans to submit a US Biologics License Application in Q1 2027.
- Are Semaglutide and Retatrutide banned in sport?
- Semaglutide is not on the WADA Prohibited List; Retatrutide is prohibited in sport by WADA under section S0.
- How do Semaglutide and Retatrutide work?
- Semaglutide is a GLP-1 receptor agonist with 94% homology to native GLP-1, modified with a C18 fatty diacid chain enabling albumin binding and once-weekly pharmacokinetics. Retatrutide is a triple incretin receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors.